

# Indian Pharmaceutical Industry

Revenues of Indian pharmaceutical companies to grow by 9-11% in FY2026


**MARCH 2025** 




#### **Agenda**













#### **Highlights**





Credit profile of Indian pharma companies is expected to remain healthy in FY2026, supported by continued strong revenue growth in both domestic and export markets and stable operating profit margins amid a benign raw material price environment. Impact of imposition of trade tariffs, if any, by the US government remains a key monitorable.



• ICRA expects the revenue growth of its sample set of Indian pharmaceutical companies<sup>1</sup> to remain healthy at 9-11% in FY2026, after an estimated 10-12% growth in FY2025. This shall be driven by a healthy increase of 8-10% each in the domestic and US markets in FY2026.



■ **Domestic market:** In 9M FY2025, revenues for ICRA's sample set companies grew by 12.2% on the back of market share gains for some players in chronic therapies, volume expansion, and continued benefits from new product introductions and acquisitions in the recent past. Revenue growth from the domestic market for ICRA's sample set companies is expected to be 8-10% in FY2026 after an estimated 11-13% in FY2025.



• **US** market: Revenues for ICRA's sample set companies moderated to 9.7% in 9M FY2025 due to the base effect and low sales of lenalidomide. That said, growth rate remains relatively higher than historical levels and is expected to remain healthy at 8-10% in FY2026, following a similar growth in FY2025 supported by continued traction for speciality molecules, ongoing product shortages and subdued pricing pressures.



 Emerging markets: ICRA expects the revenue growth for its sample set companies from the emerging markets to remain rangebound at 9-11% in FY2026, following a 9-11% expansion in FY2025. The YoY growth in 9M FY2025 stood at 10%, supported by new product launches.



• The operating profit margin (OPM) for the sample set companies is expected to remain stable at 24-25% in FY2026 in line with FY2025 estimates, supported by healthy performance in key markets, in addition to relatively stable raw material costs. Impact of depreciation of INR against the USD will remain a monitorable.



• **USFDA<sup>2</sup> inspections** have gained traction after the pandemic and higher issuances of warning letters/ import alerts have resulted in delays in product launches, translating into failure to supply penalties. These also entail significant costs towards remedial measures.



• ICRA maintains its Stable outlook for the Indian pharmaceutical industry, led by steady demand in the export and domestic markets and the comfortable credit profile of key industry participants.

<sup>&</sup>lt;sup>1</sup> ICRA's sample set of 25 leading listed Indian pharmaceutical companies; <sup>2</sup> USFDA: United States Food & Drug Administration



Name	Designation	Email	Contact Number
Shamsher Dewan	Senior Vice-President and Group Head	shamsherd@icraindia.com	+91 124 – 4545 328
Kinjal Shah	Senior Vice-President and Co-Group Head	kinjal.shah@icraindia.com	+91 22 – 6114 3442
Deepak Jotwani	Vice-President and Sector Head	deepak.jotwani@icraindia.com	+91 124 – 4545 870
Mythri Macherla	Vice-President and Sector Head	mythri.macherla@icraindia.com	+91 97011 91490
Gaurav Kushwaha	Senior Analyst	gaurav.kushwaha@icraindia.com	+91 40 – 6939 6405

















### **ICRA Business Development/Media Contact Details**

Name	Designation	Email	Contact Number
L Shivakumar	Chief Business Officer	shivakumar@icraindia.com	022-61693304
Neha Agarwal	Head – Research Sales	neha.agarwal@icraindia.com	022-61693338
Rohit Gupta	Head Business Development – Infrastructure Sector	rohitg@icraindia.com	0124-4545340
Vivek Bhalla	Head Business Development – Financial Sector	vivek.bhalla@icraindia.com	022-61693372
Vinita Baid	Head Business Development – Corporate Sector - West & East	vinita.baid@icraindia.com	033-71501131
Shivam Bhatia	Head Business Development – Corporate Sector - North & South	shivam.bhatia@icraindia.com	0124-4545803
Naznin Prodhani	Head – Group Corporate Communications & Media Relations	communications@icraindia.com	0124-4545860



















#### © Copyright, 2025 ICRA Limited. All Rights Reserved.

All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



## **Thank You!**

